Diamyd -Antigen-Specific Intralymphatic Immunotherapy
Diamyd® is a suspension for injection containing the active pharmaceutical ingredient GAD65 mixed with the vaccine adjuvant Alhydrogel (alum). The human recombinant protein GAD65 is manufactured in insect cells in a well-controlled GMP process. The manufacturing process is developed for late phase clinical use. A new manufacturing facility is being set up by Diamyd Medical in Umeå, Sweden, with a first priority to receive the process technology for the manufacture of recombinant GAD65.
Most popular related searches
insulin producing
active pharmaceutical ingredient
clinical phase
pharmaceutical ingredient
immune cell
clinical development
clinical data
antigen specificity
antigen specific
autoimmune
Preventing destruction of insulin producing cells
- Clinical data indicate the potential of Diamyd® to slow down or halt the autoimmune destruction of insulin producing beta cells. The effect is achieved through antigenspecific reprogramming of immune cells using administration of low doses of Diamyd® into superficial lymph nodes.
- Diamyd® has by preventing the autoimmune destruction of insulin producing cells, the potential to significantly reduce the complications of type 1 diabetes and LADA. Diamyd® is in Phase IIb clinical development.
